The Journal of Allergy and Clinical Immunology
Volume 120, Issue 1 , Pages 131-136 , July 2007

Regional differences in EpiPen prescriptions in the United States: The potential role of vitamin D

  • Carlos A. Camargo Jr., MD, DrPH

      Affiliations

    • From the Center for D-receptor Activation Research
    • Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
    • Corresponding Author InformationReprint requests: Carlos A. Camargo, Jr, MD, DrPH, EMNet Coordinating Center, Massachusetts General Hospital, 326 Cambridge Street, Suite 410, Boston, MA 02114.
    • ,
  • Sunday Clark, MPH, ScD

      Affiliations

    • Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
    • ,
  • Michael S. Kaplan, MD

      Affiliations

    • Department of Allergy, Kaiser Permanente, Los Angeles
    • ,
  • Philip Lieberman, MD

      Affiliations

    • University of Tennessee College of Medicine, Memphis
    • ,
  • Robert A. Wood, MD

      Affiliations

    • Division of Pediatric Allergy and Immunology, Department of Pediatrics, Johns Hopkins Medical Center, Baltimore

Received 5 September 2006 ,Revised 26 March 2007 ,Accepted 26 March 2007.

  • Image Result

    Number of EpiPen prescriptions per 1000 persons by state, ranging from 2.7 (Hawaii) to 11.8 (Massachusetts).

    Number of EpiPen prescriptions per 1000 persons by state, ranging from 2.7 (Hawaii) to 11.8 (Massachusetts).

  • Image Result

    Regional differences in EpiPen prescriptions per 1000 persons.

    Regional differences in EpiPen prescriptions per 1000 persons.

 The NDCHealth prescription data were purchased by Dey (Napa, Calif).Disclosure of potential conflict of interest: C. A. Camargo, Jr, has consulting arrangements with Dey and has received grant support from Dey and Verus. M. S. Kaplan has consulting arrangements with Dey and the EpiPen Advisory Committee and has received grant support from Genentech and the Childhood Asthma Research and Education Network. P. Lieberman has consulting arrangements with Dey and Verus; is on the speakers' bureau for Dey, Verus, Sanofi-Aventis, Genentech, Medpointe, and GlaxoSmithKline; and has served as an expert witness for Medpointe. R. A. Wood has consulting arrangements with Dey and has received grant support from Merck and Genentech. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(07)00755-5

doi: 10.1016/j.jaci.2007.03.049

The Journal of Allergy and Clinical Immunology
Volume 120, Issue 1 , Pages 131-136 , July 2007

Article Tools

* Image Usage & Resolution